Crossmark

Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial

Crossref DOI link: https://doi.org/10.1007/s00125-023-05909-4

Published Online: 2023-04-11

Published Print: 2023-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Laugesen, Christian https://orcid.org/0000-0001-9253-9457
Ranjan, Ajenthen G. https://orcid.org/0000-0002-2253-6071
Schmidt, Signe https://orcid.org/0000-0002-6968-6675
Nørgaard, Kirsten https://orcid.org/0000-0003-1620-8271
Funding

Funding for this research was provided by:

Zealand Pharma (n/a)

Steno Diabetes Center Copenhagen (n/a)
License Information

Text and Data Mining valid from 2023-04-11

Version of Record valid from 2023-04-11
More Information

Article History

Received: 15 November 2022

Accepted: 31 January 2023

First Online: 11 April 2023

Document is current

Any future updates will be listed below